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Modern anticancer therapy aims to increase the effectiveness of tumor treatment. The aim of this
work was to propose a new nanotransporter for targeted delivery of anthracycline antibiotics, which
is characterized by its bioavailability, increased uptake of the drug from the bloodstream at the site of
tumor tissue and as well as low toxicity to non-target tissue. Chitosan nanoparticles have attracted
great attention in the field of drug delivery due to their stability, low toxicity and easy preparation.
Deacetylated chitosan skeleton is composed of glucosamine units and has a high density of charged
amino groups which allow strong electrostatic interactions with biomolecules, transition metals (Zn,
Se) and peptides. We obtained the encapsulation effectiveness of chitosan 20%. Electrochemical
detection of the bounded Zn2+ ions into the chitosan structure showed shift from −099 to −0.93 V.
This result proved the formation of a chitosan-zinc complex. The ability of metallothione in to quench
the 2,2-diphenyl-1-picrylhydrazylradicalin the presence of 50 M doxorubicin was confirmed by the
change of relative absorbance in the range of 50 to 60%.
Keywords: Breast Cancer, Chitosan, Doxorubicin, Nanoparticles, Zinc.
1. INTRODUCTION
The conventional treatment of malignant tumors include
local ways such as surgery, radiotherapy with the combi-
nation of chemotherapy, hormone therapy and biological
treatment.1 For oncological patients with metastasis is the
most used chemotherapeutic doxorubicin (DOX).2 Treat-
ment response is in the range of 25% and 33%, with a
median progression of 3.6 months and a median survival of
8.9 months. Despite DOX therapeutic efficacy it exhibits
high cardiotoxicity.3 This side effect limits the cumulative
applied dose. Heart muscle damage is reported in 3% of
patients at 400 mg/m2, 7% at 500 mg/m2, and in more
than 15% of patients heart damage at 700 mg/m.4
The development of new type of nanotransporter is
focused on the decrease of DOX induced cardiotox-
icity. Several nanotechnological approaches have been
successfully used for the decrease of side effects induced
∗Author to whom correspondence should be addressed.
by various anthracycline antibiotics utilized for hema-
tological malignancies and solid tumors therapy.56 The
nanotransporter modification of therapeutics allows its tar-
geting preferentially to cancer cell and moreover could
increase level of anticancer drug in the final destina-
tion without increasing the side effects. Additionally,
drugs closed in a nano-cage are protected from intra-
cellular enzymatic degradation or endosomal transloca-
tion. Recently, chitosan nanoparticles have gained more
attention due to their stability, low toxicity and sim-
ple preparation in the field of targeted drug transport.7
Deacetylated chitosan backbone of glucosamine clusters
shows high electrostatic interactions with biomolecules,
metals (Zn, Se) and/or peptides.89
It is generally known that metallothione in (MT) is a
metal-binding protein responsible for zinc homeostasis and
heavy metal detoxification in the organism. In our previ-
ous published work, we showed the significant increase
of MT in malignant tumors.10–12 Furthermore, it has been
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estimated that the MT level in breast cancer significantly
increase due to higher metabolic activity of the tumor
tissue and defense system against oxidative stress induced
by chemotherapeutics.13–15
The aim of our study was to design a chitosan based
nanotransporter for DOX which was modified by zinc
ions (Zn-ChNPs-DOX). Zinc ions were involved for higher
uptake from the bloodstream via interaction with MT. We
suppose the free –SH groups of MT bind preferentially
to the structure of Zn-ChNPs-DOX. In the experiment,
chitosan nanotransporter was designed and subsequently
studied by biophysical methods.
2. EXPERIMENTAL DETAILS
2.1. Chemicals
Doxorubicin, chitosan, zinc chloride, metallothione in II
from rabbit liver, ssDNA (AGGATCTGATCC) ACS water
and other chemicals were purchased from Sigma-Aldrich
(St. Louis, USA) in ACS purity unless noted otherwise.
2.2. Chitosan Nanoparticles Preparation
12.5 mg of low MW chitosan was dissolved in 5 mL of 3%
acetic acid. DOX (30 M) was added to the chitosan solu-
tion under stirring (3 hours, 24 C). After DOX dissolu-
tion, the sodium tripolyphosphate (0.25% w/v) was added
dropwise. The unbounded DOX was removed using cen-
trifugation procedure. The solution was transferred in to
the tubes and centrifugated 10 min, 14000 rpm (Eppendorf
centrifuge, Hamburg, Germany). The pellet was dissolved
in 5 mL of 3% acetic acid.
2.3. Preparation of Chitosan Nanoparticles with
Encapsulated DOX Modified by Zinc
ZnCl2 was added to chitosan nanoparticles (ChNPs) with
encapsulated DOX at a final ZnCl2 concentration of
1.0 mM. The solution was stirred for 30 min before use.
2.4. Electrochemical Determination of Zinc Ions
Determination of Zn2+ by difference pulse voltamme-
try (DPV) was performed at 663 VA Stand (Metrohm,
Switzerland) connected with AUTOLAB Analyzer
(Metrohm-Autolab B.V., Utrecht, The Netherlands).
Adsorptive transfer technique and a standard cell with
three electrodes was used for measurement. A hanging
mercury drop electrode (HMDE) with a drop area of
0.4 mm2 was employed as the working electrode. An
Ag/AgCl/3 M KCl electrode acted as the reference and
platinum electrode was auxiliary. For data processing
NOVA software (Metrohm, Utrecht, The Netherlands)
was employed. The analyzed samples were deoxygenated
prior to measurements by purging with argon (99.999%).
Acetate buffer (0.2 M sodium acetate and 0.2 M acetic
acid, pH = 5) was used as a supporting electrolyte. The
parameters of the measurement were as follows: initial
potential 0 V, end potential −17 V, deoxygenating with
argon 30 s, accumulation time 120 s, step potential 5 mV,
modulation amplitude 25 mV, volume of injected sample
5 L, volume of measurement cell 2 mL (5 L of sample
and 1995 L supporting buffer).
2.5. Fluorometric and Spectroscopic
Measurements of Doxorubicin
Fluorescence spectra were acquired by a multifunctional
microplate reader Tecan Infinite 200 PRO (TECAN,
Switzerland). Excitation wavelength for DOX was 480 nm.
The fluorescence scan of DOX was measured within the
range from 510–850 nm per 2-nm steps. The detector
gain was set to 100. Absorbance of ssDNA was mea-
sured at = 260 nm. Each absorbance value is an average
of three measurements. The samples for measurements
(2 L) were placed in 96 well plate by Tecan (TECAN,
Switzerland). All measurements were performed at 25 C
controlled by the Tecan Infinite 200 PRO (TECAN,
Switzerland).
2.6. Metallothionein Scavenging of the Free Radicals
Spectrophotometric measurements of 2,2-diphenyl-1-pi-
crylhydrazyl (DPPH) were carried out using an automated
chemical analyser BS-200 (Mindray, Shenzhen, China).
Reagents and samples were placed on cooled sample holder
(4± 1 C) and automatically pipetted directly into plastic
cuvettes. Incubation proceeded at 370± 01 C. Mixture
was consequently stirred. The washing steps of pipetting
needle with distilled water (18 m) were done during the
pipetting. For detection itself, the following range of wave-
lengths were used—340, 380, 412, 450, 505, 546, 570, 605,
660, 700, 740 and 800 nm. The instrument was operated
using the BS-200 software (Mindray, Shenzhen, China).
The DPPH test is based on the ability of the sta-
ble DPPH free radical to react with hydrogen donors.
The DPPH • radical displays an intense UV-VIS absorp-
tion spectrum. In this test, a solution of radical is decol-
orized after reduction with antioxidant (AH) or a radical
(R•) in accordance with the following scheme: DPPH• +
AH → DPPH-H+A•, DPPH• +R• → DPPH-R. 150 L
of DPPH reagent was pipetted into a plastic cuvette. Sub-
sequently, 15 L of sample was added to the solution.
DPPH conducts a strong absorption in the UV-VIS spec-
trum, absorbance was measured for 12 min at = 505 nm.
To assess the production of free radicals, the absorbance
difference of the reagent without sample and reagent with
sample after ten-minute incubation was taken. After sub-
traction of the blank value the biggest absorbance differ-
ence was taken as 100% of the amount of free radicals.
The higher the amount of free radicals was, the higher was
the oxidative stress.
2.7. Ellman Assay
For analysis of thiol groups was used an Ellman spec-
trophotometric assay. 277 L of Ellman reagent (R1)
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(2 mM 5,5′-dithiobis(2-nitrobenzoic acid) in 2 mM
Na2(CH3COO2)) was pipetted in the cuvette, subsequently
the 45 L of sample and 33 L of reagent (R2) (1 M
CH3COOH) were added to the mixture. The mixture was
incubated for 10 min at 37 C. The absorbance was
recorded at 405 nm. The Ellman assay was carried out
using an automated chemical analyser BS-200 (Mindray,
Shenzhen, China). Reagents and samples were placed on a
cooled sample holder (4± 1 C) and automatically pipet-
ted directly into the plastic cuvettes. Incubation proceeded
at 370± 01 C. Mixture was consequently stirred. The
washing steps of pipetting needle with distilled water
(18 m) were done during the pipetting. The instru-
ment was operated using the BS-200 software (Mindray,
Shenzhen, China).
2.8. Descriptive Statistics
Data were processed using MICROSOFT EXCEL®
(USA). Results are expressed as mean±standard deviation
(S.D.) unless noted otherwise.
3. RESULTS AND DISCUSSION
The unique properties of chitosan were employed for DOX
delivery to the target tissue with the utilization of zinc
ions. The DOX encapsulation by chitosan polymeric cage
decorated by Zn2+ via electrostatic interaction is shown in
Figure 1. The formation of the chitosan nanoparticles and
its interaction with metallothione in is further biophysi-
cally examinated.
3.1. Chitosan Nanoparticles Characterization
We used size measurement and Z-potential characteriza-
tion of colloidal state of the nanoparticle system in our
experiment. Figure 2(A) demonstrated that size of the
nanoparticles was found to be 40± 3 nm. Measurement
Figure 1. Simplified scheme of chitosan nanotransporter focused on tumor tissue. Cancer cells highly exprime molecules of metallothionein in the
comparison with a healthy tissue.21 Designed nanotransporter Zn-ChNPs-DOX preferentially binds into the active metallothionein clusters.
of the Z-potential (or charge density) provides important
information about predicting their binding capacity. We
confirmed that chitosan nanoparticles carry positive charge
approximately of 50 mV. We tested the dependence of
tripolyphosphine (TPP) addition on Z-potential of the
formed nanoparticles. Figure 2(B) shows that the highest
Z-potential is caused by 0.0025 M addition of TPP. The
higher TPP addition causes a decrease of the Z-potential.
This effect could be explained due to the accumulation of
counterions near the surface causing charges and subse-
quently reducing the Z-potential.
3.2. Zinc Binding to the Structure of ChNPs
Electrochemical measurement was used due to its sensi-
tivity and ability to monitor the course of interactions.
Figure 2(C) shows a characteristic peak of Zn2+ with the
potential about −1.0 V. Although, chitosan alone does not
exhibit electrochemical activity and after interaction with
zinc ions the electrochemical signal shifts to more positive
potential. Simultaneously, the additional electrochemical
signal occurs at the potential about −0.2 V depending on
the zinc concentration. This result could be explained by
the formation of a zinc-chitosan complex. The dependence
of potential and electrochemical signal on zinc concentra-
tion is summarized in the graph Figure 2(D). From the
obtained data we could conclude that the higher concen-
tration of chitosan caused a decrease in the electrochem-
ical signal of zinc up to a concentration of 300 g/mL.
Therefore, higher concentrations of chitosan do not have
an effect on the zinc electrochemical signal. Simultane-
ously, we observed that the higher concentration of chi-
tosan shifts zinc electrochemical potential from −0.99 to
−0.93 V. In summary, our results confirmed the forma-
tion of a chitosan-zinc complex. Considering the fact,
that chitosan is used for electrode coating, especially in
biosensors, the observed interaction course is consistent
with other published work.16
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Figure 2. (A) The size distribution of the ChNP-DOX (0.5 M DOX, 0.0025 M TPP). MiliQ water was used as the solvent. (B) Dependence of TPP
addition (0.001–0.01 M) on ChNP-DOX Z-potential. (C) Zinc at a concentration of 100 M was titrated with 100 g/mL chitosan. (D) Dependence
of peak height and potential on chitosan concentration (0–1000 g/mL) for the complex formation. Measurement was carried out in acetate buffer,
pH 5.0, DPV with a 90 s accumulation time.
3.3. Doxorubicin Encapsulation
We involved a fluorescence as a suitable analytical tool
for characterization and determination the encapsulation
efficiency of chitosan nanoparticles. 3 M DOX shows 9%
quantum yield which enables the sensitive detection.17
Firstly, the dependence of fluorescence signal on DOX
concentration was evaluated. The obtained calibration
curve shows a linear trend in the concentration range
from 0 to 30 M with the following linear equation: y =
16012x+20123 and R2 = 09944 (Fig. 3(A)). The limit
of DOX fluorometric detection was found to be 0.09 M
(3 S/N). For the determination of the encapsulation effi-
ciency, the doxorubicin itself (30 M) and encapsulated
DOX (DOX-ChNPs) fluorescence intensity was compared.
The decrease of the fluorescence intensity for DOX-ChNPs
could be observed from the emission spectra (Fig. 3(B)).
The concentration of an encapsulated DOX was calcu-
lated to be 6 M which corresponds to 20% encapsulation
effectivity.
The goal of our study was to encapsulate DOX into
chitosan nanoparticles and to minimize the number of
molecules on the nanoparticles surface. We took the advan-
tage of DOX intercalation ability into the structure of
DNA to determine the presence of DOX (30 M) on
ChNPs surface. The intercalated DOX into the (1 mM)
DNA showed a significant decrease of the fluorescence
signal (Fig. 3(C), on top). Consequently, the DOX-ChNPs
was analyzed before and after the purification step which
removes unbounded DOX. The obtained results demon-
strated a higher fluorescence signal for the unpurified
DOX-ChNPs which could be explained due to the removal
of unbound DOX. In the presence of DNA, the fluores-
cence signal decrease occurs in both cases. To evaluate
the changes of fluorescence signals the size of the differ-
ence was calculated before and after purification of ChNP-
DOX. The higher decrease oft he fluorescence signal was
estimated in the case of unpurified DOX-ChNPs which
means that DOX appears on the surface of the nanopar-
ticles at low concentration. Obtained results are in good
agreement with other studies based on the doxorubicin-
chitosan nanoparticle formation.18–20 Our approach excels
in the simplicity and availability of the experimental
design.
3.4. ChNPs-DOX Interaction with MT
One proposed mechanism of action of DOX after its
metabolization is the formation of a number of radicals,
which lead to a cell damage and later to apoptosis. In
several malignant tumors there is a significant increase of
thiol levels (explained by the increase of MT synthesis),
that presumably scavenge molecules used for damaging
the tumor cells. Due to this effect, the tumor cell resistance
for the used cytostatic increases. In our study, we aimed to
assess the effect of thiols capable of capturing the radicals,
especially MT. To date, very little attention has been paid
to this issue and mechanisms of these interactions have not
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Figure 3. (A) Dependence of doxorubicin concentration (0–30 M) on fluorescence signal. (B) Difference in emission wavelengths of DOX-
chitosan (doxorubicin concentration 30 M) and purified DOX-ChNPs. (C) Characterization of DOX (6 M) position on the crosslinked nanoparticle
using DNA.
been described yet. In this experiment, DPPH radical was
used.
Figure 4(A) shows the effect of DOX added to the
DPPH reaction mixture at different concentrations. The
observed signals are within a 10% deviation due to a
laboratory error, and the resultant DPPH signal does
not change at any of the tested doxorubicin concentra-
tions. MT (1000 g/mL) scavenged the DPPH radical
very intensively (signal change by more than 200%), see
Figure 4(B). In case that DOX was added to the MT,
Figure 4. Interaction study of DOX with MT in the assessment of the capacity to scavenge DPPH radical. (A) Effect of DOX at defined concentrations
(0, 1.9, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500 and 1000 M on the resulting signal. (B) Addition of MT (1000 g/mL) to the DPPH radical in the
presence of defined concentrations of DOX, free –SH of the thiol group were analysed by the Ellman method (405 nm). (C) Changes in the DPPH
radical signal in the presence of defined DOX concentrations and 1000, 500, 250, 125, 62 and 31 g/mL MT. The interaction study was performed
immediately after mixing DOXO and MT (1:1) in an automatic mode (5 L of sample) at 37 C. The results were evaluated from the reaction curve
and recalculated to a relative signal, where 100% was always a DPPH with MT. The relative changes of the DPPH signal were determined by the
photometric method (537 nm), see Material and Methods for further details.
the progressive blocking of the -SH groups for Ellman’s
reagent (Fig. 4(B), grey bars) was observed with the
increase of the DOX concentration, and after 100 M
addition of DOX the resulting MT signal change was more
than 100%.
The results indicate the considerable ability of MT to
quench the DPPH radical in the presence of 50 M DOX,
the signal change was found to be between 50–60%.
Figure 4(C) shows the effect of different amounts of MT
and its ability to quench the DPPH radical. The result
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clearly demonstrated the notable ability of thiol com-
pounds to react with radical molecules and thus reduce the
effectiveness of antitumor treatment (1 g of MT reacts
with DPPH by changing the signal by 0.2145). For these
reasons, it is necessary to look for suitable tools to over-
come this natural biological base of resistance.
4. CONCLUSION
To the conclusion, new nanotransporter is characterized
by its bioavailability, increased uptake of drug from the
blood stream at the site of tumor tissue, and low toxicity
to non-targeted tissues. The results showed that the chi-
tosan nanoparticle closes DOX in its structure and Zn2+
ions are bound to its surface. DOX-ChNPs of size 40 nm
were successfully designed. The fluorescence quenching
effect of doxorubicin was used for the evaluation of non-
encapsualted DOX molecules on the nanoparticle sur-
face. The results demonstrated the formation of chitosan
nanoparticles and their ability to bind on the MT protein,
which plays an important role in the breast cancer.
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